病院感染対策ガイドライン(結核症)

Similar documents


結核の接触者健康診断の手引き(改訂第4版)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo

28 1 1a 1b 2 MRI T2 3 CT C3 N95 N95 6ml 90

indd


Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

Table 1 Characteristics of the study participants in Imari municipal hospital

untitled

大学論集第42号本文.indb

26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira


Dec THE JAPANESE JOURNAL OF ANTIBIOTICS Clostridium difficile Clostridium difficile C. difficile Clostridium difficile inf

審査報告書(案)

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates


SBP hospitalist network.key

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study



C/NC : committed/noncommitted

アセトアミノフェンお知らせ文書_案_ _ver09.doc

VOL. 43 NO. 4

HPV HPV HPV HPV 7 HPV 8 9 HPV 3 HPV HPV HPV , Becker Ajzen H


診療ガイドラインのカラクリ

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

小児感染免疫第27巻第4号

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST

CHEMOTHERAPY FEB Table 1 Background of volunteers

Atlas_j060419

ICT 1 21 ICT., Cooper, Dawson

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

untitled

Fig. 1 Chemical structure of DL-8280

フィナレビ106号.indb

1_2.eps

(Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24


動くレントゲン

Juntendo Medical Journal

Ⅰ. 緒言 Suzuki, et al., Ⅱ. 研究方法 1. 対象および方法 1 6 表 1 1, 調査票の内容 図

〈企業特集:検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi

よこ組/001~000 医療系総合大学における


評論・社会科学 85号(よこ)(P)/3.佐分

76 1 2

Core Ethics Vol. : - NICU : : - A B C D

HPM_442_F_TgCHG_1128



untitled


Perspective-Taking Perspective-Taking.... Vol. No.

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi

第26回日本環境感染学会総会プログラム・抄録集 Part1

好酸球性副鼻腔炎:診断ガイドライン(JESREC Study)

Transcription:

1 11. 2 Abe C, Hirano K, Wada M, et al. Resistance to Mycobacterium tuberculosis to four first line antituberculosis drugs in Japan, 1997. Int J Tubercle Lung Dis 2001;5:46-52. 3 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, Supplement 2: Diagnosis and Treatment of Latent TB Infection and Active TB, 1994. 4 ATS, CDC:Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47. 5 :2. 2000. 2000p13-18. 6 Metchock BG, Nolte FS, Wallace RJ,Jr:Mycobacterium. In:Manual of Clinical Microbiology (Lennete EH, et al. ed, 7 th ed). ASM, NY (1999) P399-437. 7 :3. 2000. 2000p19-26. 8 :4. 2000. 2000p27-42. 9 :6. 2000. 2000p78-95. 10 Iinuma Y, Ichiyama S, Yamori S, et al. Diagnostic value of the Amplicor PCR assay for initial diagnosis and assessment of treatment response for pulmonary tuberculosis. Microbiol Immunol 1998;42:281-287. 11 ASM: Clinical Microbiology Procedures Handbook, vol. 2, Section 14. Biohazards and Safety. ASM, Washington, DC. 1995. 12 CDC and NIH:Biosafety in Microbiological and Biomedical Laboratories 4 th ed, 1999. 13 CDC:Goals for working safety with Mycobacterium tuberculosis in clinical, public health, and research laboratories, 1997. 14 Garner JS, the Hospital Infection Control Practices Advisory Committee. Guidelines for Isolation Precautions in Hospitals. Am J Infect Control 1996;24:24-31. 15 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, Supplement 1 : Determining of the Infectiousness of a TB Patient, 1994. 16 Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet1999;353(9151):444-9. 17 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : E. Management of Hospitalized Patients Who Have Confirmed or Suspected TB, 1994. 18 Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144. 19 van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179. 20 Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001;163:717-20. 21 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : F. Engineering Control Recommendations, 1994. 22 Riley RL. Airborne infection. Am J Med 1974;57:466-75. 23 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : G. Respiratory Protection, 1994. 24 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, Supplement 5: Decontamination-Cleaning, Disinfecting, and Sterilizing of Patient-Care Equipment, 1994. 25 CDC : Screening for Tuberculosis and Tuberculosis Infection in High-Risk Populations, 1995. 26 Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, I E. 19 and II G. 19 Tuberculosis. Infect Control Hosp Epidemiol 1998;19:407-63. 27. 7 1989 28 CDC:The Role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States, 1996. 29 Rodrigues L, Diwan D, Wheeler J. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8.

30 Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702. 31 Comstock GW : How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-850. 32 Chaisson RE. New developments in the treatment of latent tuberculosis. Int J Tuberc Lung Dis. 2000;4:S176-81. 33. 2 3. 2000. 34 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : D. Management of Patients Who May Have Active TB in Ambulatory-Care Setting and Emergency Departments, 1994. 35 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : H. Cogh-Inducing and Aerosol-Generating Procedures, 1994. 36 CDC : Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, II Recommendations : M. Additional considerations for selected areas in health-care facilities and other health-care settings, 1994. 37. 3 3. 2000. 38 Driver CR, Valway SE, Morgan WM, et al., Transmission of Mycobacterium tuberculosis associated with air travel. JAMA 1994;272:1031-5. 39 Yusuf HR, Braden CR, Greenberg AJ, et al., Tuberculosis transmission among five school bus drivers and students in two New York counties. Pediatrics 1997;100:E9.